Table 4.
EGFR biomarker and treatment efficacy
| EGFR biomarker | No. | Pathology SCC | Smoking never | Response CR+PR | PFS (mo) |
|---|---|---|---|---|---|
| EGFR wild type | 60 | 56 (93) | 4 (7) | 3 (5) | 1.9 |
| EGFR mutation type | 4 | 4 (100) | 0 | 2 (50) | 2.9 |
| Exon 19 deletion | 1 | SCC | Ex-smoker | CR | 23.2 |
| Exon 20 G810S | 1 | SCC | Ex-smoker | PR | 2.9 |
| Exon 20 V786M | 1 | SCC | Ex-smoker | PD | 1.0 |
| Exon 21 G863S | 1 | SCC | Ex-smoker | SD | 5.2 |
| EGFR/FISH negativity | 56 | 54 (96) | 3 (5) | 3 (5) | 1.9 |
| EGFR/FISH positivity | 5 | 4 (80) | 1 (20) | 2 (40) | 3.6 |
| High polysomy | 1 | SCC | Current smoker | PR | 5.4 |
| High polysomy | 1 | SCC | Ex-smoker | SD | 4.0 |
| Gene amplification | 1 | NSCLC-NOS | Never smoker | PR | 3.6 |
| Botha) | 1 | SCC | Current smoker | PD | 1.0 |
| Botha) | 1 | SCC | Ex-smoker | PD | 0.9 |
| EGFR/IHC negativity | 24 | 21 (88) | 4 (17) | 1 (4) | 3.6 |
| EGFR/IHC positivity | 32 | 32 (100) | 1 (3) | 4 (12.5) | 1.9 |
| 2+ | 16 | 16 (100) | 0 | 1 (6) | 1.0 |
| 3+ | 16 | 16 (100) | 1 (6) | 3 (19) | 1.9 |
Values are presented as number (%). EGFR, epidermal growth factor receptor; SCC, squamous cell carcinoma; CR, complete response; PR, partial response; PFS, progression-free survival; FISH, fluorescence in situ hybridization; IHC, immunohistochemistry.
a)
Highpolysomy and gene amplification.